Small‐molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual‐inhibiting properties for bladder cancer treatment

• Published in: Exploration (Beijing, China) Vol. 3; no. 5; pp. 20220141 - n/a
• Main Authors: Li, Guoyin, Song, Zewen, Ru, Yi, Zhang, Jing, Luo, Lianxiang, Yang, Wei, Wu, Hao, Jin, Haibao, Bao, Xuanwen, Wei, Di, Yan, Zhao, Qu, Haijing, Zhu, Zheng, Xue, Xiangdong, Zhou, Gang
• Format: Journal Article
• Language: English
• Published: China John Wiley & Sons, Inc 01.10.2023; Wiley
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Apoptosis; Biocompatibility; Bladder; Bladder cancer; Cancer; Cancer therapies; Cell cycle; Chemotherapy; Epidermal growth factor; epidermal growth factor receptor (EGFR); Epidermal growth factor receptors; Genes; Growth factors; Hesperidin; high drug loading; In vivo methods and tests; Kinases; Malignancy; Nanoparticles; Natural products; NMR; Nuclear magnetic resonance; Proteins; Receptors; Self-assembly; Software; Solvents; Succinic acid; Survival; Toxicity; Triptolide; Tyrosine; triptolide; epidermal growth factor receptor (EGFR); bladder cancer; high drug loading; hesperidin

Bladder cancer (BCa) is one of the most common malignancies worldwide. Although multiple efforts have been made, the 5‐year survival rate of patients with BCa remains unchanged in recent years. Overexpression of the epidermal growth factor receptor (EGFR) is found in ≈74% of BCa tissue specimens; ho...